Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd. is a clinical-stage oncology company based in Jerusalem, Israel, that is pioneering intratumoral alpha-emitting radiotherapeutics to address multiple solid tumor types, including those with few or no currently viable treatment options. The company's core technology, the Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy), is a delivery system designed to harness the naturally powerful properties of alpha particles to treat tumors with precision while potentially sparing nearby healthy cells. According to the company, the Alpha DaRT is engineered for both superficial and deep-seated tumors and is intended to integrate seamlessly into existing physician workflows. Alpha Tau's mission, as stated on its website, began with the insight that cancer patients should receive powerful therapy delivered directly into the tumor without the harsh side effects associated with conventional systemic therapies and external beam radiation. The company argues that current treatments often damage surrounding healthy tissue and are frequently given in small doses stretched over many cycles or fractions. The Alpha DaRT is designed to allow patients to receive an ultra-high dose of localized treatment in a single session with minimal side effects. The company is evaluating the Alpha DaRT across a wide range of cancer patient needs, including as both a stand-alone therapy and in combination strategies with systemic agents; as a treatment for many tumor types, from superficial skin tumors to those in deep-seated organs; and as a therapy for both metastatic and inoperable disease. Therapeutic applications highlighted by the company include pancreatic cancer, superficial skin and head and neck cancer, brain cancer, prostate cancer, lung cancer, and immune system activation. The clinical pipeline spans from early-stage pre-clinical research to global, multi-center clinical trials. Alpha Tau Medical is publicly traded on the NASDAQ under the ticker symbol DRTS. The company is led by CEO and Chairman Uzi Sofer, alongside a leadership team that includes Chief Medical Officer Robert Den, MD; Chief Financial Officer Raphi Levy; Chief Technology Officer Ronen Segal; Chief Operations Officer Amnon Gat; and Chief Scientific Officer and Co-Inventor Prof. Yona Keisari. Its board of directors includes Uzi Sofer, Nadav Kidron, Maya Netser, and Dr. David M. Milch. The company maintains a corporate governance framework with audit, compensation, and nominating/governance and sustainability committees, and provides investor relations resources including a newsroom, conferences, and patient support materials.

Alpha Tau Medical Ltd. is a clinical-stage oncology company headquartered in Jerusalem, Israel. The company was founded around the insight that cancer patients should receive powerful therapy delivered directly into the tumor without the harsh side effects associated with conventional treatments. This founding principle is described on the company's website, which states that Alpha Tau began with the belief that existing systemic therapies and external beam radiation, while effective against cancer cells, typically cause damage to surrounding healthy tissue and are often administered in small doses over many cycles or fractions. To address this unmet need, the company developed the Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy), a technology designed to harness the naturally powerful properties of alpha particles to treat tumors with precision while potentially sparing nearby healthy cells. The Alpha DaRT is engineered for both superficial and deep-seated tumors and is intended to integrate seamlessly into existing physician workflows. The company's stated mission is to allow patients to receive an ultra-high dose of localized treatment in a single session with minimal side effects. Alpha Tau Medical is publicly traded on the NASDAQ under the ticker symbol DRTS. The company is led by CEO and Chairman Uzi Sofer, with a leadership team that includes Chief Medical Officer Robert Den, MD; Chief Financial Officer Raphi Levy; Chief Technology Officer Ronen Segal; Chief Operations Officer Amnon Gat; and Chief Scientific Officer and Co-Inventor Prof. Yona Keisari. Its board of directors includes Uzi Sofer, Nadav Kidron, Maya Netser, and Dr. David M. Milch. The company maintains a corporate governance framework with audit, compensation, and nominating/governance and sustainability committees, and provides investor relations resources including a newsroom, conferences, and patient support materials. The company is evaluating the Alpha DaRT across a wide range of cancer patient needs, including as both a stand-alone therapy and in combination strategies with systemic agents; as a treatment for many tumor types, from superficial skin tumors to those in deep-seated organs; and as a therapy for both metastatic and inoperable disease. Therapeutic applications highlighted by the company include pancreatic cancer, superficial skin and head and neck cancer, brain cancer, prostate cancer, lung cancer, and immune system activation. The clinical pipeline spans from early-stage pre-clinical research to global, multi-center clinical trials.

Clinical-stage oncology company pioneering intratumoral alpha-emitting radiotherapeutics for solid tumors with high unmet need.

• Alpha DaRT®

  Diffusing Alpha-emitters Radiation Therapy — an intratumoral alpha-emitting radiotherapeutic delivery system for solid tumors.

1. 1Alpha Tau Medical: Alpha Radiation Cancer Treatmentalphatau.com
2. 2About Us - Alpha Tau Medical: Alpha Radiation Cancer Treatmentalphatau.com
3. 3Corporate Governance - Alpha Tau Medical: Alpha Radiation Cancer Treatmentalphatau.com
4. 4Alpha Tau Medical Ltd. (Israel) - Wikidatawikidata.org